The cost effectiveness of misoprostol prophylaxis alongside long term nonsteroidal anti-inflammatory drugs: Implications of the MUCOSA trial

PharmacoEconomics

Volumn 17, Issue 3, 2000, Pages 295-304

  Davey, Peter J ^a   Meyer, Eric ^b  

^a M TAG   (Australia)

^b Monsanto Company Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; ECONOMIC EVALUATION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

EID: 0034004082     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017030-00007     Document Type: Article

References (23)

1. 1. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061-5
2. 2. Al M, Michel B, Rutten F. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. Pharmacoeconomics 1996; 10: 141-51
3. 3. Bentkover JD, Baker AM, Kaplan H. Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. Pharmacoeconomics 1994; 5: 335-42
4. 4. De Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheumatol 1992; 96 Suppl. 1: 49-53
5. 5. Edelson JT, Tosteson AN, Sax P. Cost-effectiveness of misoprostol for prophylaxis against anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990; 264: 41-7
6. 6. Gabriel SE, Jaakimainen R, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal anti-inflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993; 36: 447-59
7. 7. Gabriel SE. Has the cost-effectiveness of misoprostol been underestimated? [letter]. Arch Intern Med 1995; 155: 1448
8. 8. Gabriel SE. Has the cost-effectiveness of misoprostol been underestimated?. Arch Intern Med 1995; 155: 1451-2
9. 9. Gabriel SE. Economic evaluation using mathematical models: the case of misoprostol prophylaxis. J Rheumatol 1995; 22: 1412-4
10. 10. Jonsson B. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care 1992; 8: 234-44
11. 11. Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990; 66: 639-46
12. 12. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9
13. 13. Commonwealth of Australia Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee including major submissions involving economic analysis. Canberra: Australian Government Publishing Service, 1995
14. 14. Stucki G, Sangha O. Kritische Beurteilung von okonomischen Analysen am Beispiel der Misoprostol-Prophylaxe anti-rheumatika-induzierter Gastropathien [abstract]. Z. Rheumatol 1994; 53: 37-45
15. 15. The efficacy and safety of misoprostol in the prevention of NSAID-induced serious GI complications, 1994. Study report: S81-94-06-093. Crows Nest, NSW: Searle, 1994
16. 16. Commonwealth of Australia Department of Human Services and Health. Report on the development of AN-DRG version 3 cost weights. Canberra: Department of Human Services and Health, 1995
17. 17. Commonwealth of Australia Department of Human Services and Health. Medicare benefits schedule. Canberra: Australian Government Publishing Service, 1999
18. 18. Commonwealth of Australia Department of Health and Family Services. Schedule of pharmaceutical benefits. Canberra: J.S. McMillan Printing Group, 1998
19. 19. Australian Institute of Health and Welfare. Health expenditure bulletin number 13. Canberra: Australian Institute of Health and Welfare, 1997
20. 20. Henry D, Johnston A, Dobson A, et al. Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin and corticosteroids. BMJ 1987; 295: 1227-9
21. 21. Australian Bureau of Statistics. Deaths Australia 1996. Canberra: Australian Bureau of Statistics, 1997
22. 22. George B, Harris T, Mitchell A. Reimbursement decisions and the implied value of life: cost effectiveness analysis and decisions to reimburse pharmaceuticals in Australia 1993-1996. In: Harris A, editor. Economics and health: 1997. Proceedings of the Nineteenth Australian Conference of Health Economists; 1997; Melbourne. Sydney: School of Health Services Management, University of New South Wales, 1998: 1-18. (Australian Studies in Health Service Administration Series; 85)
23. 23. Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-91